Testosterone Science

Research Summaries

Androgen Society Position Paper on Cardiovascular Risk With Testosterone Therapy

Population: Men

Citation

Androgen Society Position Paper on Cardiovascular Risk With Testosterone Therapy

Morgentaler A, Dhindsa S, Dobs AS, et al.

Mayo Clin Proc. 2024;99(11):1785-1801. Published October 22, 2024.

PMID: 39436329 DOI: 10.1016/j.mayocp.2024.08.008

Study at a Glance

Design
Position paper of the Androgen Society, prepared by a 9-member international panel with affiliations in urology, endocrinology, andrology, cardiology, family medicine, and biochemistry, in response to the TRAVERSE trial (Lincoff et al., 2023; Morgentaler et al., 2024)
Sources searched
Not specified; no search strategy, databases, or inclusion criteria were reported
Period covered
Publications from 1939 to 2024, including historical reports of testosterone treatment for angina and peripheral vascular disease
Evidence base presented
5 studies suggesting increased cardiovascular risk, 25 selected randomized controlled trials (RCTs), 27 selected observational and registry studies, and 20 meta-analyses
Population of included studies
Men with testosterone deficiency (hypogonadism), including older men, men with type 2 diabetes or prediabetes, and men with established cardiovascular disease
Outcomes of interest
Major adverse cardiovascular events (MACE: myocardial infarction, stroke, cardiovascular death), venous thromboembolism, atrial fibrillation, and mortality
Evidence grading method
None reported

Question Addressed

The panel set out to determine whether testosterone therapy in men with testosterone deficiency increases the risk of myocardial infarction, stroke, or cardiovascular death. The paper also examined whether the evidence that led to the 2015 Food and Drug Administration (FDA) cardiovascular labeling still holds after publication of the TRAVERSE trial (Lincoff et al., 2023; Morgentaler et al., 2024; US FDA, 2015).

Plain Language Summary

Between 2010 and 2014, 1 small clinical trial and 2 studies based on medical records suggested that testosterone treatment might increase the risk of heart attack and stroke [1,4,12]. In 2015, the FDA added a warning about this possible risk to testosterone labels and asked manufacturers to carry out a large safety study [10]. That study, called TRAVERSE, included 5246 men aged 45 to 80 years with low testosterone who already had heart disease or a high risk of it. About 7 in every 100 men had a heart attack, stroke, or heart-related death, whether they used testosterone gel or a placebo gel [6].

In this paper, a group of experts from the Androgen Society reviewed TRAVERSE and many earlier studies. They concluded that testosterone treatment, when used in men with low testosterone, does not raise the risk of heart attack, stroke, or heart-related death [7]. In 2025, the FDA told manufacturers to remove the heart risk language from the boxed warning on testosterone labels and to add a warning that testosterone can raise blood pressure [11].

Some questions remain. In TRAVERSE, men who used testosterone had slightly more irregular heartbeat (atrial fibrillation), kidney injury, and blood clots in the lungs [6]. Many men stopped treatment during the study, and the study lasted about 3 years, so effects of longer use are less certain [3,5]. Testosterone can also raise the red blood cell count, which needs regular blood tests [2,13]. Men considering testosterone treatment should discuss their heart health, blood pressure, and blood test monitoring with their doctor.

Methods

The paper is a narrative review with a critical appraisal of selected studies. It does not describe a systematic literature search, prespecified eligibility criteria, risk-of-bias assessment, or formal evidence grading. The evidence is organized in 4 parts:

  • Endogenous testosterone and outcomes: Prospective cohort studies of serum testosterone concentrations in relation to all-cause mortality, cardiovascular mortality, and cardiovascular events
  • Studies suggesting increased risk: Detailed appraisal of 5 publications (1 RCT stopped early, 2 retrospective observational studies, 1 meta-analysis, and 1 imaging substudy of an RCT), summarized in Table 1 of the paper
  • Studies indicating no increased or reduced risk: Tabulated summaries of selected RCTs (Table 2), observational and registry studies (Table 3), and meta-analyses (Table 4), with a narrative description of 3 large multicenter RCTs: the Testosterone Trials (T Trials), T4DM, and TRAVERSE
  • Other cardiovascular risks: Narrative discussion of atrial fibrillation, pulmonary embolism and venous thromboembolism, and erythrocytosis

Key Findings

  • Studies reporting increased risk: Of the studies that directly examined testosterone therapy and cardiovascular risk or mortality, the panel identified 5 that suggested harm and judged the supporting evidence to be weak in each case (Morgentaler et al., 2024).
    • TOM trial (2010): In 209 older men with mobility limitation, 23 men in the testosterone arm and 5 in the placebo arm had cardiovascular-related adverse events (Basaria et al., 2010). The trial was not designed to assess cardiovascular outcomes and events were not adjudicated. Of the 4 MACE, all occurred in the testosterone arm (Morgentaler et al., 2024).
    • Veterans Affairs cohort (2013): At 3 years after coronary angiography, the corrected Kaplan-Meier estimated cumulative event rate was 25.7% with testosterone therapy and 19.9% without (absolute risk difference 5.8%; 95% CI, −1.4% to 13.1%) (Vigen et al., 2013). The panel reported that crude event rates were 10.1% and 21.2%, respectively, and noted 2 published corrections and a request for retraction from 29 medical societies (Morgentaler et al., 2024).
    • Meta-analysis (2013): Testosterone therapy was associated with increased cardiovascular-related events (odds ratio 1.54; 95% CI, 1.09 to 2.18) (Xu et al., 2013). The panel noted that this analysis included a trial of high-dose oral testosterone in men with alcoholic cirrhosis and that 2 component studies with incorrect event counts accounted for 46% of events (Morgentaler et al., 2024).
    • Insurance claims cohort (2014): The rate ratio for nonfatal myocardial infarction in the 90 days after versus the 12 months before a testosterone prescription was 1.36 (95% CI, 1.03 to 1.81), and 2.19 (95% CI, 1.27 to 3.77) in men aged 65 years or older (Finkle et al., 2014). The panel considered the 2 time windows not comparable, because prescribing decisions after a recent infarction would lower the pre-prescription rate (Morgentaler et al., 2024).
    • Coronary plaque substudy (2017): Noncalcified plaque volume increased more with testosterone than with placebo (estimated difference 41 mm³; 95% CI, 14 to 67; P=.003). Calcium scores did not differ, placebo-group plaque volume was higher at baseline, and no MACE occurred in the 170 men enrolled (Morgentaler et al., 2024).
  • TRAVERSE trial: In 5246 men aged 45 to 80 years with symptomatic hypogonadism and preexisting cardiovascular disease or high cardiovascular risk (mean age 63 years; median testosterone 227 ng/dL; 55% with preexisting cardiovascular disease), MACE occurred in 7.0% of men receiving testosterone gel and 7.3% receiving placebo gel (Morgentaler et al., 2024). The hazard ratio was 0.96 (95% CI, 0.78 to 1.17; P<.001 for noninferiority), and the individual MACE components and the secondary end point that added coronary revascularization did not differ between groups (Lincoff et al., 2023).
  • Other large RCTs: In the T Trials (790 men aged 65 years or older), MACE totaled 9 with testosterone and 16 with placebo over 2 years (Morgentaler et al., 2024). In T4DM (men aged 50 to 74 years with impaired glucose tolerance or newly diagnosed type 2 diabetes), MACE numbered 2 with testosterone and 6 with placebo (Morgentaler et al., 2024). The investigators of both trials stated that their data were insufficient to establish cardiovascular safety (Snyder et al., 2016; Wittert et al., 2021).
  • Smaller RCTs: The selected RCTs reported no increase in MACE. Several reported improvements in angina threshold, exercise capacity in heart failure, insulin resistance, glycemic control, and components of the metabolic syndrome (Morgentaler et al., 2024).
  • Observational and registry studies: None of the 27 tabulated studies reported increased cardiovascular risk. Several reported lower MACE or mortality with testosterone therapy, and 1 large cohort found lower rates only when serum testosterone was normalized (Morgentaler et al., 2024).
  • Meta-analyses: Of 20 meta-analyses on cardiovascular risk, 19 found no increase; the 2013 meta-analysis was the only exception (Morgentaler et al., 2024).
  • Atrial fibrillation and pulmonary embolism: In TRAVERSE, atrial fibrillation occurred in 91 men receiving testosterone and 63 receiving placebo, and pulmonary embolism in 24 and 12, respectively (Morgentaler et al., 2024). The panel judged these differences to be of uncertain clinical significance, because total venous thromboembolic events did not differ between arms (Morgentaler et al., 2024).
  • Erythrocytosis: Citing the Endocrine Society guideline, the panel noted that neuro-occlusive events in men who develop erythrocytosis during testosterone therapy have been infrequent, and proposed that concern about erythrocytosis be reevaluated (Morgentaler et al., 2024).
  • Endogenous testosterone: Cohort studies consistently associated low serum testosterone with higher all-cause and cardiovascular mortality. In an individual participant data analysis of 9 cohorts (255,830 participant-years), testosterone below 7.4 nmol/L (213 ng/dL) was associated with higher all-cause mortality and below 5.3 nmol/L (153 ng/dL) with higher cardiovascular mortality (Morgentaler et al., 2024).

Limitations and Strengths Affecting Interpretation

Strengths

  • The paper brings together RCT, observational, and meta-analytic evidence on cardiovascular safety of testosterone therapy in 1 document (Morgentaler et al., 2024).
  • Each study that reported increased cardiovascular risk is appraised in detail, including design, event ascertainment, published corrections, and data errors (Morgentaler et al., 2024).
  • The main conclusion rests on TRAVERSE, a large placebo-controlled trial designed to assess MACE in men with hypogonadism and preexisting or high cardiovascular risk (Lincoff et al., 2023).
  • The panel included specialists in urology, endocrinology, andrology, cardiology, family medicine, and biochemistry from the United States, the United Kingdom, and Germany (Morgentaler et al., 2024).

Limitations

  • The paper is a narrative review without a reported search strategy, eligibility criteria, risk-of-bias assessment, or evidence grading, and the tables are described as selected studies (Morgentaler et al., 2024). Selection bias cannot be excluded.
  • Studies reporting harm are appraised in detail, while observational and registry studies reporting benefit are summarized without a comparable assessment of confounding or prescribing bias (Morgentaler et al., 2024). Reported benefits in these studies are associations and do not establish causation.
  • In TRAVERSE, more than 60% of participants discontinued treatment, and the mean treatment duration (21.7 months) was shorter than the mean follow-up (33.0 months) (Budoff, 2023; Lincoff et al., 2023). This can bias a noninferiority comparison toward finding no difference.
  • TRAVERSE tested a single transdermal formulation at physiological target concentrations (Lincoff et al., 2023). The results cannot be directly extended to injectable formulations, supraphysiological doses, younger men, or treatment over many years. An individual participant data meta-analysis noted that long-term safety data are limited (Hudson et al., 2022), and the T Trials and T4DM investigators stated that their trials could not establish cardiovascular risk (Snyder et al., 2016; Wittert et al., 2021).
  • The panel describes the conclusion as definitive and beyond reasonable doubt, which goes further than a noninferiority trial with a mean follow-up of about 3 years can show (Lincoff et al., 2023; Morgentaler et al., 2024).
  • Several authors report consulting fees, honoraria, or research support from manufacturers of testosterone products (Morgentaler et al., 2024).
  • The text and tables contain several numerical and citation inconsistencies, including sample sizes, meta-analysis counts, and reference attributions (Morgentaler et al., 2024).

Read this paper as a society position statement that summarizes RCT evidence, led by TRAVERSE, showing no increase in MACE with physiological testosterone therapy in men with confirmed hypogonadism over 2 to 3 years. Questions about long-term safety, injectable or high-dose regimens, atrial fibrillation, venous thromboembolism, and blood pressure require trials that measure these outcomes over longer periods.

Authors' Conclusions

The panel concluded that TRAVERSE, together with the earlier literature, shows that testosterone therapy in men with testosterone deficiency does not increase the risk of myocardial infarction, stroke, or cardiovascular death. The authors regard the question as settled and see no need for further research on it. They also stated that the FDA should remove the cardiovascular warning from testosterone product labeling, since the trial the agency required found no increase in MACE (Morgentaler et al., 2024).

Commentary

This position paper does not contribute new data. Its value is that it brings together the evidence on cardiovascular safety of testosterone therapy and places it alongside TRAVERSE, the first large RCT designed to assess MACE in men with hypogonadism (Lincoff et al., 2023; Morgentaler et al., 2024). In TRAVERSE, the primary composite end point occurred in 7.0% of men receiving testosterone and 7.3% receiving placebo (hazard ratio 0.96; 95% CI, 0.78 to 1.17), which met the prespecified noninferiority criterion (Lincoff et al., 2023). This result is consistent with an individual participant data meta-analysis of 35 placebo-controlled RCTs, in which cardiovascular events occurred in 7.5% of men receiving testosterone and 7.2% receiving placebo (odds ratio 1.07; 95% CI, 0.81 to 1.42) (Hudson et al., 2022). The earlier signals of harm came from an RCT stopped early for non-adjudicated cardiovascular adverse events (Basaria et al., 2010), 2 retrospective observational studies (Finkle et al., 2014; Vigen et al., 2013), and 1 meta-analysis of trials not designed to assess cardiovascular outcomes (Xu et al., 2013). The TOM investigators themselves stated that the small size of the trial and its specific population did not allow broader inferences about safety (Basaria et al., 2010).

For clinical practice, the most relevant finding is that in men aged 45 to 80 years with confirmed hypogonadism and established cardiovascular disease or multiple risk factors, transdermal testosterone titrated to 350 to 750 ng/dL did not increase MACE over a mean follow-up of 33.0 months (Lincoff et al., 2023). The paper also notes that men treated to normal serum testosterone in observational cohorts had lower event rates than men whose concentrations did not normalize (Morgentaler et al., 2024). This is consistent with the Endocrine Society recommendation to target testosterone concentrations in the mid-normal range during treatment (Bhasin et al., 2018).

TRAVERSE also reported a higher incidence of atrial fibrillation, acute kidney injury, and pulmonary embolism with testosterone (Lincoff et al., 2023). The position paper discusses atrial fibrillation and pulmonary embolism but does not address acute kidney injury (Morgentaler et al., 2024). Hematocrit monitoring remains relevant: in T4DM, the safety threshold for hematocrit above 54% was reached in 22% of men receiving testosterone undecanoate injections compared with 1% receiving placebo (Wittert et al., 2021). Ambulatory blood pressure monitoring studies required by the FDA confirmed a class-wide increase in blood pressure with testosterone products (US FDA, 2025). The Endocrine Society guideline, published before TRAVERSE, recommends against starting testosterone therapy in men with elevated hematocrit, uncontrolled heart failure, myocardial infarction or stroke in the previous 6 months, or thrombophilia (Bhasin et al., 2018).

The regulatory context has changed since the paper was published. In 2015, the FDA required labeling on a possible increased risk of heart attack and stroke and stated that the benefits and safety of testosterone for age-related low testosterone had not been established (US FDA, 2015). In February 2025, after reviewing TRAVERSE, the FDA recommended adding the trial results to all testosterone product labels and removing language from the Boxed Warning on increased risk of adverse cardiovascular outcomes. The agency kept the limitation of use for age-related hypogonadism and required new warnings on increased blood pressure based on ambulatory blood pressure monitoring studies (US FDA, 2025). The panel's call for removal of the cardiovascular warning is therefore in line with the subsequent FDA action. In June 2026, the US Department of Health and Human Services announced that the FDA is requesting removal of the limitation of use for age-related hypogonadism, together with revised prostate cancer and benign prostatic hyperplasia warnings (US HHS, 2026). These were described as requested label changes and should be checked against current prescribing information.

Clinicians can use this paper as a consolidated account of the evidence behind the 2025 labeling changes, while the decision to treat an individual man still depends on confirmed hypogonadism, baseline cardiovascular and hematological status, and monitoring of hematocrit and blood pressure during therapy (Bhasin et al., 2018; Lincoff et al., 2023; US FDA, 2025).

References

1. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109-122.

DOI: | PubMed: PMID

Supporting quote: "associated with an increased risk of cardiovascular adverse events"

2. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.

DOI: | PubMed: PMID

Supporting quote: "myocardial infarction or stroke within the last 6 months, or thrombophilia"

3. Budoff MJ. Testosterone repletement: is it the TRAVERSE trial or a travesty? JACC Adv. 2023;2(10):100742.

DOI: | PubMed: PMID

Supporting quote: "with more than 60% of the participants discontinuing therapy"

4. Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9(1):e85805.

DOI: | PubMed: PMID

Supporting quote: "the risk of MI following initiation of TT prescription is substantially increased"

5. Hudson J, Cruickshank M, Quinton R, et al. Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis. Lancet Healthy Longev. 2022;3(6):e381-e393.

DOI: | PubMed: PMID

Supporting quote: "We found no evidence that testosterone increased short-term to medium-term cardiovascular risks"

6. Lincoff AM, Bhasin S, Flevaris P, et al; TRAVERSE Study Investigators. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117.

DOI: | PubMed: PMID

Supporting quote: "A primary cardiovascular end-point event occurred in 182 patients (7.0%) in the testosterone group"

7. Morgentaler A, Dhindsa S, Dobs AS, et al. Androgen Society position paper on cardiovascular risk with testosterone therapy. Mayo Clin Proc. 2024;99(11):1785-1801.

DOI: | PubMed: PMID

Supporting quote: "it has been conclusively determined that TTh is not associated with increased risk"

8. Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611-624.

DOI: | PubMed: PMID

Supporting quote: "The number of participants was too few to draw conclusions about the risks"

9. US Department of Health and Human Services. HHS announces requested updates to testosterone therapy product labels. News release. June 18, 2026.

URL: (not indexed in PubMed; no DOI)

Supporting quote: "Remove the limitation of use stating that the safety and effectiveness"

10. US Food and Drug Administration. FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. March 3, 2015.

URL: (not indexed in PubMed; no DOI)

Supporting quote: "there is a possible increased cardiovascular risk associated with testosterone use"

11. US Food and Drug Administration. FDA issues class-wide labeling changes for testosterone products. February 28, 2025.

URL: (not indexed in PubMed; no DOI)

Supporting quote: "removing language from the Boxed Warning related to an increased risk"

12. Vigen R, O'Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829-1836. Published corrections appear in JAMA. 2014;311(3):306 and JAMA. 2014;311(9):967.

DOI: | PubMed: PMID

Supporting quote: "the use of testosterone therapy was associated with increased risk of adverse outcomes"

13. Wittert G, Bracken K, Robledo KP, et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes Endocrinol. 2021;9(1):32-45.

DOI: | PubMed: PMID

Supporting quote: "Longer-term durability, safety, and cardiovascular effects of the intervention remain to be further investigated."

14. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108.

DOI: | PubMed: PMID

Supporting quote: "Testosterone therapy increased the risk of a cardiovascular-related event"

All Research Summaries

Post a Comment or Question

Shared Decision Making

Bring the Evidence to Your Next Consultation

Use our patient resources and questionnaires to prepare questions about symptoms, testing and treatment options for your doctor.